RU2437583C2 - Применение дгк (dha), эпк (epa) или эпк, полученных из дгк, для лечения патологии, связанной с окислительным повреждением клетки, a также их нетерапевтические применения - Google Patents

Применение дгк (dha), эпк (epa) или эпк, полученных из дгк, для лечения патологии, связанной с окислительным повреждением клетки, a также их нетерапевтические применения Download PDF

Info

Publication number
RU2437583C2
RU2437583C2 RU2008126805/13A RU2008126805A RU2437583C2 RU 2437583 C2 RU2437583 C2 RU 2437583C2 RU 2008126805/13 A RU2008126805/13 A RU 2008126805/13A RU 2008126805 A RU2008126805 A RU 2008126805A RU 2437583 C2 RU2437583 C2 RU 2437583C2
Authority
RU
Russia
Prior art keywords
dha
epa
glyceride
therapeutic use
specified
Prior art date
Application number
RU2008126805/13A
Other languages
English (en)
Russian (ru)
Other versions
RU2008126805A (ru
Inventor
ПЕДРОЛ Хоан Карлес ДОМИНГО (ES)
Педрол Хоан Карлес Доминго
ГАРСИА Хосе Антонио ВИЛЬЕГАС (ES)
ГАРСИА Хосе Антонио ВИЛЬЕГАС
Original Assignee
Бруди Текнолоджи, С.Л.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37728386&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2437583(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from ES200503202A external-priority patent/ES2277557B1/es
Application filed by Бруди Текнолоджи, С.Л. filed Critical Бруди Текнолоджи, С.Л.
Publication of RU2008126805A publication Critical patent/RU2008126805A/ru
Application granted granted Critical
Publication of RU2437583C2 publication Critical patent/RU2437583C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36—Carboxylic acids; Salts or anhydrides thereof
    • A61K8/361—Carboxylic acids having more than seven carbon atoms in an unbroken chain; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Birds (AREA)
  • Emergency Medicine (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Pain & Pain Management (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Toxicology (AREA)
RU2008126805/13A 2005-12-21 2006-12-20 Применение дгк (dha), эпк (epa) или эпк, полученных из дгк, для лечения патологии, связанной с окислительным повреждением клетки, a также их нетерапевтические применения RU2437583C2 (ru)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
ES200503202A ES2277557B1 (es) 2005-12-21 2005-12-21 Utilizacion de acido docosahexaenoico para el tratamiento del daño celular oxidativo.
ESP-200503202 2005-12-21
ES200602417A ES2315124B1 (es) 2005-12-21 2006-09-25 Mejoras en el objeto de la patente principal p 200503202, por "utilizacion de acido docosahexaenoico para el tratamiento del daño oxidativo celular".
ES200602418A ES2315125B1 (es) 2005-12-21 2006-09-25 Mejoras en el objeto de la patente principal p 200503202, por "utilizacion de acido docosahexaenoico para el tratamiento del daño oxidativo celular".
ESP-200602417 2006-09-25
ESP-200602418 2006-09-25
ESP-200603231 2006-12-20
ES200603231A ES2316263B1 (es) 2005-12-21 2006-12-20 Mejoras en el objeto de la patente principal p 200503202, por "utilizacion de acido docosahexaenoico para el tratamiento del daño oxidativo celular".
PCT/EP2006/070016 WO2007071733A2 (en) 2005-12-21 2006-12-20 Use of dha, epa or dha-derived epa for treating a pathology associated with cellular oxidative damage

Publications (2)

Publication Number Publication Date
RU2008126805A RU2008126805A (ru) 2010-01-27
RU2437583C2 true RU2437583C2 (ru) 2011-12-27

Family

ID=37728386

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2008126805/13A RU2437583C2 (ru) 2005-12-21 2006-12-20 Применение дгк (dha), эпк (epa) или эпк, полученных из дгк, для лечения патологии, связанной с окислительным повреждением клетки, a также их нетерапевтические применения

Country Status (16)

Country Link
US (3) US9265745B2 (https=)
EP (3) EP2510927A3 (https=)
JP (1) JP2009523414A (https=)
KR (1) KR101256448B1 (https=)
CN (1) CN101346138B (https=)
AU (1) AU2006327064B2 (https=)
BR (1) BRPI0621131A2 (https=)
CA (1) CA2632949C (https=)
ES (1) ES2384701T3 (https=)
IL (1) IL192154A (https=)
MX (1) MX2008008171A (https=)
NO (1) NO341240B1 (https=)
NZ (1) NZ569676A (https=)
PL (1) PL1962825T3 (https=)
RU (1) RU2437583C2 (https=)
WO (1) WO2007071733A2 (https=)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8252742B2 (en) * 2004-12-30 2012-08-28 Hill's Pet Nutrition, Inc. Methods for enhancing the quality of life of a senior animal
ES2277557B1 (es) 2005-12-21 2008-07-01 Proyecto Empresarial Brudy, S.L. Utilizacion de acido docosahexaenoico para el tratamiento del daño celular oxidativo.
US9265745B2 (en) 2005-12-21 2016-02-23 Brudy Technology S.L. Use of DHA, EPA or DHA-derived EPA for treating a pathology associated with cellular oxidative damage
US20100119600A1 (en) 2007-06-01 2010-05-13 Joar Opheim Substances for reducing occurrence of major cardiac events comprising red yeast rice extract and omega-3 polyunsaturated fatty acid or derivative thereof
US8343753B2 (en) 2007-11-01 2013-01-01 Wake Forest University School Of Medicine Compositions, methods, and kits for polyunsaturated fatty acids from microalgae
US8207363B2 (en) 2009-03-19 2012-06-26 Martek Biosciences Corporation Thraustochytrids, fatty acid compositions, and methods of making and uses thereof
DK2429317T4 (da) * 2009-04-17 2019-05-13 Natac Pharma S L Sammensætninger med højt indhold af omega-3-fedtsyrer og med lavt indhold af phytansyre
WO2011090493A1 (en) 2010-01-19 2011-07-28 Martek Biosciences Corporation Eicosapentaenoic acid-producing microorganisms, fatty acid compositions, and methods of making and uses thereof
US20120252888A1 (en) * 2011-03-29 2012-10-04 Palupa Medical Ltd. Compositions and Methods for Treating Neurologic Disorders
US10709680B2 (en) * 2011-07-18 2020-07-14 Physicians Recommended Nutriceuticals, Llc Methods for treating dry eye
US20160310456A1 (en) * 2013-03-12 2016-10-27 Physicians Recommended Nutriceuticals, Llc Compositions and methods for using same for reducing levels of arachidonic acid in tissue having undergone an invasive procedure
HK1198515A1 (en) 2011-07-21 2015-05-15 Dsm Ip Assets B.V. Fatty acid compositions
WO2014134184A1 (en) 2013-02-28 2014-09-04 Anida Pharma Inc. Methods of treating ototoxicity
CN103585140A (zh) * 2013-11-22 2014-02-19 苏州麦可旺志生物技术有限公司 Epa在制备溴酸钾诱导氧化应激性肾损伤药物中的应用
US11718577B2 (en) 2013-12-18 2023-08-08 Commonwealth Scientific And Industrial Research Organisation Lipid compositions comprising triacylglycerol with long-chain polyunsaturated fatty acids
NZ721036A (en) * 2013-12-18 2023-07-28 Grains Res & Dev Corp Lipid comprising long chain polyunsaturated fatty acids
TWI725937B (zh) 2014-06-06 2021-05-01 美商海洋原料公司 ω-３組成物、劑型及使用方法
KR20180051737A (ko) * 2016-11-08 2018-05-17 차의과학대학교 산학협력단 대장염-관련 암 발생을 줄이는 ω-3 폴리불포화지방산 활성 성분으로 포함하는 항암 조성물
US20170150690A1 (en) 2017-02-13 2017-06-01 Bayer Cropscience Lp Cotton variety fm 1888gl
US20170156280A1 (en) 2017-02-13 2017-06-08 Bayer Cropscience Lp Cotton variety st 5517gltp
JP7133306B2 (ja) * 2017-12-01 2022-09-08 国立大学法人九州大学 アシルステリルグルコシド、アシルステリルグルコシドの製造方法、組成物、抗酸化剤、血中脂質低下剤、抗肥満剤、抗腫瘍剤及びアテローム性動脈硬化症の予防又は治療剤
US12226390B2 (en) 2019-07-21 2025-02-18 Scf Pharma Inc. Cannabinoids compositions with polyunsaturated fatty acid monoglycerides, methods and uses thereof
CN110846346B (zh) * 2019-11-26 2021-06-22 瞿瀚鹏 富含Sn-2位DHA的微生物油脂及其制备方法和应用
WO2023012690A1 (en) * 2021-08-04 2023-02-09 Leiutis Pharmaceuticals Llp Novel omega 3 carrier preparations for inhalation drug delivery for treating lung inflammation
CN113749255B (zh) * 2021-09-15 2022-11-29 江南大学 一种磷脂组合物在修复肌肉损伤的应用
KR20240128906A (ko) * 2021-12-28 2024-08-27 에스씨에프 파마 인코포레이티드 다중불포화 지방산 모노글리세리드, 이의 조성물, 방법 및 용도
CN116687902A (zh) * 2023-06-14 2023-09-05 浙江大学 Dha在制备促进心肌细胞增殖和心脏再生产品中的应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2218984A (en) * 1988-05-27 1989-11-29 Renafield Limited High-concentration mixtures of polyunsaturated fatty acids and their esters derived from animal &/or vegetable oils, & their prophylactic or therapeutic uses
RU2205004C2 (ru) * 1997-07-22 2003-05-27 Виатрис Гмбх Унд Ко. Кг. Терапевтические и диетические композиции, содержащие необходимые жирные кислоты и биологически активные дисульфиды
WO2004112776A2 (en) * 2003-06-23 2004-12-29 Advanced Bionutrition (Europe) Limited Inflammatory disease treatment
WO2005013908A2 (en) * 2003-08-05 2005-02-17 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Neuroprotection protects against cellular apoptosis, neural stroke damage, alzheimer’s disease and retinal degeneration

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2524217B2 (ja) * 1988-04-18 1996-08-14 マルハ株式会社 脳機能改善組成物、学習能力増強剤、記憶力増強剤、痴呆予防剤または痴呆治療剤
GB2223943A (en) 1988-10-21 1990-04-25 Tillotts Pharma Ag Oral disage forms of omega-3 polyunsaturated acids
SE9101642D0 (sv) * 1991-05-30 1991-05-30 Kabi Pharmacia Ab Phospholipids
CA2119000A1 (en) * 1993-03-19 1994-09-20 David Frederick Horrobin Formulation for use in smokers
CA2164291C (en) * 1993-06-09 2007-10-30 David John Kyle Methods and pharmaceutical compositions useful for treating neurological disorders
US20050027004A1 (en) 1993-06-09 2005-02-03 Martek Biosciences Corporation Methods of treating senile dementia and Alzheimer's diseases using docosahexaenoic acid and arachidonic acid compositions
JPH07255417A (ja) * 1994-03-25 1995-10-09 Kanebo Ltd 機能性健康食品
FR2731015B1 (fr) * 1995-02-24 1997-05-30 Sci Sartone Procede d'enrichissement enzymatique d'huiles d'origine marine et les triglycerides d'acides gras polyinsatures ainsi obtenus
AU5346296A (en) 1995-04-17 1996-11-07 Japan As Represented By Director-General Of Agency Of Industrial Science And Technology Novel microorganisms capable of producing highly unsaturated fatty acids and process for producing highly unsaturated fa tty acids by using the microorganisms
MY118354A (en) * 1995-05-01 2004-10-30 Scarista Ltd 1,3-propane diol derivatives as bioactive compounds
JP3558423B2 (ja) * 1995-09-11 2004-08-25 旭化成ケミカルズ株式会社 ドコサヘキサエン酸を構成脂肪酸とするリン脂質の製造方法
JP3985035B2 (ja) * 1995-09-14 2007-10-03 独立行政法人産業技術総合研究所 （ｎ−６）系ドコサペンタエン酸含有油脂ならびに該油脂の製造方法および用途
WO1998028978A1 (en) 1996-05-08 1998-07-09 Weider Nutrition Group, Inc. Structured glycerols and structured phosphatides
DE69737063T2 (de) * 1996-07-23 2007-07-19 Nagase Chemtex Corp. Verfahren zur herstellung von decosahexaensäure und decosapentsäure
US6313167B1 (en) 1997-06-16 2001-11-06 Nippon Suisan Kaisha Ltd. Composition having capability of removing risk factor during exercise
JPH11239465A (ja) * 1997-06-16 1999-09-07 Nippon Suisan Kaisha Ltd 健常人が運動能力を高める食品
JPH11239464A (ja) * 1997-06-16 1999-09-07 Nippon Suisan Kaisha Ltd 運動時の危険因子除去能を有する組成物
GB9901809D0 (en) 1999-01-27 1999-03-17 Scarista Limited Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes
IT1308613B1 (it) * 1999-02-17 2002-01-09 Pharmacia & Upjohn Spa Acidi grassi essenziali nella prevenzione di eventi cardiovascolari.
JP2002040014A (ja) * 2000-07-19 2002-02-06 Nippon Steel Corp 炭素含有耐火物の耐摩耗性、耐食性及び耐酸化性の評価方法
EP1249523A1 (fr) * 2001-04-12 2002-10-16 Michel Beckers Cylindre brouilleur et son utilisation
ITMI20020269A1 (it) * 2002-02-12 2003-08-12 Victorix Assets Ltd Uso di steri etilici di acidi poliinsaturi omega-3 in pazienti con insufficienza cardiaca
AR039170A1 (es) 2002-03-28 2005-02-09 Bio Dar Ltd Co-granulos de dha y romero y metodos de uso
US20040209953A1 (en) * 2002-12-06 2004-10-21 Wai Lee Theresa Siu-Ling Glyceride compositions and methods of making and using same
US7041840B2 (en) * 2002-12-18 2006-05-09 Alberta Research Council Inc. Antioxidant triacylglycerols and lipid compositions
JP2005000033A (ja) * 2003-06-10 2005-01-06 Shinbijuumu:Kk 食品
JP2005068060A (ja) * 2003-08-22 2005-03-17 Nrl Pharma Inc ラクトフェリンを含有する医薬組成物ならびに加工食品の製造法
US20050130937A1 (en) * 2003-10-22 2005-06-16 Enzymotec Ltd. Lipids containing omega-3 and omega-6 fatty acids
US7267830B2 (en) * 2003-12-19 2007-09-11 Alcon, Inc. Composition and methods for inhibiting the progression macular degeneration and promoting healthy vision
WO2006121421A2 (en) 2004-01-14 2006-11-16 Robert Ritch Methods and formulations for treating glaucoma
ITMI20040069A1 (it) 2004-01-21 2004-04-21 Tiberio Bruzzese Uso di composizioni di acidi grassi n-3 ad elevata concentrazione per il trattamento di disturbi del sistema nervoso centrale
US20090054523A1 (en) 2005-01-24 2009-02-26 Morten Bryhn Use of a Fatty Acid Composition Containing DHA for the Production of a Medical Product or a Food Stuff for the Treatment of Amyloidos-Related Diseases
FR2882894B1 (fr) 2005-03-11 2009-04-03 Larena Sa Composition alimentaire suppletive
ES2264886B1 (es) * 2005-05-12 2008-02-01 Proyecto Empresarial Brudy, S.L. Utilizacion de acido docosahexaenoico para el tratamiento de enfermedades tumorales.
US9265745B2 (en) 2005-12-21 2016-02-23 Brudy Technology S.L. Use of DHA, EPA or DHA-derived EPA for treating a pathology associated with cellular oxidative damage

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2218984A (en) * 1988-05-27 1989-11-29 Renafield Limited High-concentration mixtures of polyunsaturated fatty acids and their esters derived from animal &/or vegetable oils, & their prophylactic or therapeutic uses
RU2205004C2 (ru) * 1997-07-22 2003-05-27 Виатрис Гмбх Унд Ко. Кг. Терапевтические и диетические композиции, содержащие необходимые жирные кислоты и биологически активные дисульфиды
WO2004112776A2 (en) * 2003-06-23 2004-12-29 Advanced Bionutrition (Europe) Limited Inflammatory disease treatment
WO2005013908A2 (en) * 2003-08-05 2005-02-17 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Neuroprotection protects against cellular apoptosis, neural stroke damage, alzheimer’s disease and retinal degeneration

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
WATKINS STEVEN M ET AL: "Docosahexaenoic acid accumulates in cardiolipin and enhances HT-29 cell oxidant production" JORNAL OF LIPID RESEARCH, vol. 39, no.8, August 1998, p.1583-1588. *

Also Published As

Publication number Publication date
MX2008008171A (es) 2008-11-12
ES2384701T1 (es) 2012-07-11
EP1962825B1 (en) 2014-04-02
KR20080081334A (ko) 2008-09-09
EP3263101A1 (en) 2018-01-03
EP2510927A3 (en) 2013-05-01
WO2007071733A2 (en) 2007-06-28
NO20083187L (no) 2008-09-19
US9259408B2 (en) 2016-02-16
CN101346138A (zh) 2009-01-14
CA2632949C (en) 2012-05-22
US20080292681A1 (en) 2008-11-27
ES2384701T3 (es) 2014-07-02
CN101346138B (zh) 2013-03-13
JP2009523414A (ja) 2009-06-25
US20130274337A1 (en) 2013-10-17
KR101256448B1 (ko) 2013-04-19
BRPI0621131A2 (pt) 2011-11-29
AU2006327064B2 (en) 2012-04-26
EP2510927A2 (en) 2012-10-17
IL192154A0 (en) 2008-12-29
CA2632949A1 (en) 2007-06-28
US20160151258A1 (en) 2016-06-02
IL192154A (en) 2015-04-30
WO2007071733A3 (en) 2007-09-07
NO341240B1 (no) 2017-09-25
RU2008126805A (ru) 2010-01-27
US9265745B2 (en) 2016-02-23
NZ569676A (en) 2012-03-30
AU2006327064A1 (en) 2007-06-28
PL1962825T3 (pl) 2014-09-30
EP1962825A2 (en) 2008-09-03

Similar Documents

Publication Publication Date Title
RU2437583C2 (ru) Применение дгк (dha), эпк (epa) или эпк, полученных из дгк, для лечения патологии, связанной с окислительным повреждением клетки, a также их нетерапевтические применения
US20240148690A1 (en) Compositions comprising urolithin compounds
JP2009523414A5 (https=)
Tulini et al. Development of solid lipid microparticles loaded with a proanthocyanidin-rich cinnamon extract (Cinnamomum zeylanicum): Potential for increasing antioxidant content in functional foods for diabetic population
WO2006035900A1 (ja) コエンザイムｑ１０含有乳化組成物
KR100926170B1 (ko) 엽산이 혼입된 대두 발효 고분자물질 및 이를 포함하는조성물
JP6010665B2 (ja) 筋肉増量剤
US20230066836A1 (en) Antioxidant Extracts and Compositions
US20070098761A1 (en) Processed fat composition for preventing/ameliorating lifestyle-related diseases
JP6083942B2 (ja) 長命草及び魚介油を含む組成物
Averina et al. Encapsulation of alimentary bioactive oils of the Baikal Lake area into pH-sensitive micro-and nanoparticles
CN110691590A (zh) 用于预防和/或改善脑功能障碍的含有叶黄素类或其盐和菱属植物的加工产物的组合物
JP6217986B2 (ja) 徐放性機能材の製造方法
JP7344661B2 (ja) 食品組成物の製造方法
WO2012157290A1 (ja) 非アルコール性脂肪性肝炎の予防改善剤
EP2464713B1 (fr) Procede de preparation d'un jus integral d'olive, composition obtenue selon ce procede et son application dans le domaine de la cosmetique et de la dietetique
KR100987518B1 (ko) 엽산이 혼입된 대두 발효 고분자물질 및 이를 포함하는 조성물
CN103989171B (zh) 一种抗衰老美容养颜软胶囊及其制备工艺
CN107232497A (zh) 一种具有降血脂功能的膨化食品及其制备方法
WO2008023425A1 (fr) Composition pour l'amélioration de l'état de la peau
JP2015528696A (ja) 醸造プロセスのバイオマスから得られる脂肪バインダー
JP2011051952A (ja) 皮膚角質層水分量の増加用組成物およびその経口摂取用製剤
JP2023058457A (ja) 炎症性皮膚疾患の予防、治療又は改善剤
JP6538395B2 (ja) 抗酸化剤
KR20100004903A (ko) 엽산이 혼입된 대두 발효 고분자물질 및 이를 포함하는 조성물